US 9688764
Methods of treating breast cancer by administering anti-human prolactin receptor (PRLR) antibodies
granted A61KA61K2039/505A61K31/537
Quick answer
US patent 9688764 (Methods of treating breast cancer by administering anti-human prolactin receptor (PRLR) antibodies) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Jun 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 47
- CPC classes
- A61K, A61K2039/505, A61K31/537, A61K47/68031, A61K47/68033